Literature DB >> 7614518

Coronary problems associated with altitude and air travel.

J K Alexander1.   

Abstract

Hypoxia accompanying acute exposure to high altitude engenders augmented sympathetic nervous activity, thus increasing heart rate and blood pressure and the risk of effort angina and dysrhythmia in coronary patients. This risk is highest during the first 1 to 3 days and diminishes in 5 to 7 days as sympathetic activity subsides. Protective effects may result from 1. Gradual ascent. 2. Attention to blood pressure control. 3. Limitation of activity to less than the symptom-limiting degree at sea level, especially during the first 1 to 3 days. 4. Preexisting exercise tolerance of modest-to-moderate degree. 5. Ability of patient to appraise heart rate and blood pressure. Ascent by high-risk patients can be recommended to no more than moderate altitude, where adequate facilities for cardiovascular care are proximate. The risk of acute mountain sickness is not increased in older coronary patients. Strong contraindications to air travel by coronary patients would appear to be 1. New-onset angina. 2. Unstable angina. 3. Frequent or high-grade ventricular ectopy. 4. Severe or poorly controlled hypertension. Myocardial infarction within several weeks or months constitutes a relative contraindication, with persistent angina, ventricular ectopy, and poor ventricular function as the factors of greatest concern.

Entities:  

Mesh:

Year:  1995        PMID: 7614518

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  2 in total

1.  Myocardial infarction in a 21-year-old healthy man on rapid ascent.

Authors:  Y C Huang; I-T Chu
Journal:  Emerg Med J       Date:  2006-11       Impact factor: 2.740

2.  Increased myocardial blood flow during acute exposure to simulated altitudes.

Authors:  P A Kaufmann; C Schirlo; V Pavlicek; T Berthold; C Burger; G K von Schulthess; E A Koller; A Buck
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.